| Bioactivity | Promestriene is a synthetic diethyl-ether of estradiol and a locally effective estrogen. Promestriene has an efficient action on vaginal atrophy while it is minimally absorbed[1][2]. | ||||||||||||
| Invitro | Promestriene is an analogue of oestradiol which is minimally absorbed and devoid of systemic effects when administered intravaginally, either as gynecological cream or capsules[2].Topical Promestriene is minimally absorbed with chronic use and has been reported to significantly improve the symptoms of vaginal atrophy[3]. | ||||||||||||
| Name | Promestriene | ||||||||||||
| CAS | 39219-28-8 | ||||||||||||
| Formula | C22H32O2 | ||||||||||||
| Molar Mass | 328.49 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Isabel Santos, et al. Urogenital Disorders Associated With Oestrogen Deficiency: The Role of Promestriene as Topical Oestrogen Therapy. Gynecol Endocrinol. 2010 Sep;26(9):644-51. [2]. Lino Del Pup, et al. Promestriene, a Specific Topic Estrogen. Review of 40 Years of Vaginal Atrophy Treatment: Is It Safe Even in Cancer Patients. Anticancer Drugs. 2013 Nov;24(10):989-98. [3]. AJO Almodovar, et al. Abstract P5-05-07: Promestriene effects on estrogen-sensitive breast cancer cell proliferation in vitro. Cancer Res 2013;73(24 Suppl): Abstract nr P5-05-07. |